Inflammatory Bowel Disease

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, recaps results from the SEQUENCE trial, which were presented at Digestive Disease Week 2024.

WASHINGTON — In this video, Mark Genovese, MD, discusses results of the VIVID-1 study, in which mirikizumab demonstrated noninferiority to ustekinumab for week 52 clinical remission among patients with moderate to severe Crohn’s disease.

WASHINGTON — Patients with Crohn’s disease who ate a catered low-fat, high-fiber diet for 8 weeks experienced improvements in symptoms, inflammation and quality of life vs. those offered counseling alone, researchers reported.

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.

WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.

WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.

In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.

Novel forms of a rare genetic variant may contribute to the risk for co-occurring Parkinson’s disease and inflammatory bowel disease, according to research presented in Genome Medicine.

Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.

Tumor necrosis factor inhibitor use was independently associated with a greater risk for progressive kidney function decline but not risk for all-cause mortality among patients with new-onset inflammatory bowel disease, according to data.